BTIG initiated coverage of Harrow (HROW) with a Buy rating and $62 price target The company has 16 important products, most of which it considered to be best in class, and the key to a Harrow investment is that the company continues to both drive growth of existing products and to acquire new products where the Harrow footprint is a powerful advantage to commercialization, the analyst tells investors in a research note. BTIG adds that it expects Harrow’s near-term and ongoing updates on the progress of these approaches and signs that the company is on track to meet 2025 revenue guidance of $280M to be the key catalysts for the stock over the remainder of 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health’s Strategic Expansion and Growth Potential in Branded Pharmaceuticals
- Harrow initiated with an Outperform at William Blair
- Harrow acquires U.S. commercial rights to BYQLOVI 0.05% from Formosa
- Harrow acquires commercial rights for Byqlovi 0.05%
- Harrow Health’s Earnings Call: Strong Growth Amid Challenges